In an effort to identify cellular proteins that may be involved in the Abelson murine leukemia virus (AMuLV) transformation process, we have isolated a hybridoma antibody (6C3) that detects a tumor-associated antigen in all A-MuLV-induced pre-B-cell lymphomas. The 6C3 antibody immunoprecipitates two molecules of Mr 160,000 and Mr 125,000 from metabolically labeled A-MuLV tumors. The two proteins recognized by the 6C3 antibody are distinct from the A-MuLV-transforming protein in that they lack viral gag determinants and are neither phosphoproteins nor protein kinases. The 6C3 proteins can be detected in all A-MuLV pre-Bcell lymphomas and some nonviral B lymphomas but are not detected on any other tumor or normal cell, including AMuLV-transformed fibroblast lines. Thus, the 6C3 proteins may represent the products of novel cellular genes whose expression is induced, stabilized, or amplified in B-cell tumors of both viral and nonviral origin. Further evidence in support of this hypothesis is provided by the finding that 6C3 antigen expression correlates with autonomous cell growth and the transformed phenotype in both normal bone marrow cultures and those infected with A-MuLV.
Abelson murine leukemia virus (A-MuLV) is a rapidly transforming retrovirus that transforms fibroblasts and bone marrow cells in vitro (1, 2) and induces lymphoid tumors in vivo (3) . The product of the A-MuLV genome (v-abl) has been shown to be a phosphoprotein that possesses an associated protein kinase activity capable of phosphorylating tyrosine residues in vitro (4, 5) . Although the expression of the AMuLV gene product correlates with A-MuLV transformation (6, 7) , several recent findings suggest that A-MuLV expression may not be necessary or sufficient for maintaining the transformed state. (i) Early after A-MuLV infection of bone marrow cultures in vitro, cells require an adherent cell feeder layer for growth even though v-abl expression and protein kinase activity are similar to those of established tumors (8, 9) . Only after a period of weeks in culture do these A-MuLV-infected cell lines acquire the capacity for autonomous growth (9) . (ii) Clonal lines of A-MuLV-induced tumors can lose the A-MuLV proviral genome in vivo while still retaining the fully transformed phenotype (10) . Some of these tumor lines show increased transcription of two cellular oncogenes, c-myb and c-myc (11, 12) . (iii) The cellular transforming sequences from A-MuLV-induced tumors identified by transfection into NIH-3T3 cells are distinct from the A-MuLV gene product (13) . Taken together, these results suggest that A-MuLV expression may be the initiating event in a multistep process involving the activation or induction of other transformation-related proteins of cellular origin.
In this paper we report the isolation and characterization of a monoclonal antibody (6C3) that detects transformationassociated proteins in murine B-cell lymphomas that are distinct from the A-MuLV gene product (v-abl) and its normal cellular counterpart (c-abl). The animals and cell suspensions were prepared in cell suspending medium with 5% fetal calf serum. Long-term bone marrow cultures were established by using the method previously described (14) .
Antibodies. The 6C3 antibody was prepared by a modification of the technique of Galfre et al. (15) (25, ,000 cpm/0.025 ml) as described (17 NaDodSO4/PAGE. Labeled samples (0.025-0.05 ml) were run on 8% NaDodSO4/PAGE slab gels for 2 hr at 150 V. Gels were fixed in methanol/acetic acid/water, 50:10:40, for 1 hr and then rinsed in distilled water for 1 hr. Gels were treated with 1 M sodium salicylate for an additional hour, dried, and then exposed to Kodak XAR-5 film for 1-3 days. RESULTS Isolation of a Monoclonal Antibody Specific for B-Cell Lymphomas. As part of a project to isolate T-killer cell-specific antibodies, Fisher rats were immunized with a mixture of AMuLV tumor-specific T-cell clones (1E4) and their A-MuLV pre-B-cell target (L1-2) in complete Freund's adjuvant. During the screening of the resulting hybridomas, one antibody of the IgG2A subclass was identified (6C3) that showed high levels of binding to the L1-2 target rather than to the T-killer cell clone. This hybridoma was subsequently cloned at limiting dilution and grown to larger volume for further testing against a panel of tumor cells and normal tissues.
The 6C3 antibody binds to all A-MuLV pre-B lymphomas but does not react with any normal cell population ( (Fig. 1) . These same two, proteins are immunoprecipitated from all 6C3 antigen-positive cell lines tested, including the non-AMuLV-induced B-lymphoma NBL; neither protein is immunoprecipitated from any 6C3 antigen-negative cell line (data not shown). When L1-2 cells are surface iodinated by using the lactoperoxidase method, only p1606C3 is precipitated ( Fig. 1) , indicating that p1606C3 is the serologically defined cell surface antigen detected in the binding assays. When the same immunoprecipitations were run under nonreducing conditions to preserve disulfide linkages, the 6C3 proteins were found to occur predominantly as dimers of Mr 320,000 and Mr 250,000 (Fig. 1) (Fig. 1) , the molecules recognized by the 6C3 antibody are similar in size to the products of the AKMuLV genome: p120abl and p160abl (19) . Thus, it was important to establish the relationship, if any, between the 6C3 proteins and the AMuLV-transforming gene products. As shown in Fig. 2 , preclearing of a L1-2 cell extract with anti-gag antibodies removes all of the pl20abl from the cell lysate, consistent with the presence of a portion of the M-MuLV gag at the NH2 terminus of pl20abl (6, 7) . However, the same method of preclearing fails to remove any of the p12563 or p1606C3 from the same extract, indicating that these proteins do not contain viral gag determinants. In addition, Fig. 3 beled with inorganic phosphate and do not possess in vitro protein kinase activity. Thus, we conclude that the 6C3 proteins represent B-lymphoma-specific proteins distinct from A-MuLV gene products.
Although the 6C3 proteins do not correspond to any known A-MuLV-encoded protein, they could still be related to the normal cellular counterpart of the A-MuLV-transforming protein c-abl. The product of the c-abl gene is a protein of Mr 150,000 (NCP150) (20) , which is expressed at high levels within normal lymphoid tissues (21) . However, the 6C3 proteins are not detected in thymus or any other normal lymphoid tissue either by radioimmunoassay (Table 1) or by immunoprecipitation, even when using 10-fold excess of normal cells (Fig. 4) . The absence of the 6C3 proteins from normal lymphoid tissues argues strongly against any relationship with NCP150.
6C3 Expression Correlates with a Transformed Phenotype. Recently, it has become possible to establish long-term cultures of normal pre-B and B lymphocytes on adherent bone marrow feeder layers (14) . These lymphocytes can be cultured for many months and still retain a strong requirement for the feeder layer for in vitro growth. Although such cells are not tumorigenic in vivo, B lineage cells capable of in vivo tumor production do arise in a fraction of the cultures after many months of passage and these cells no longer require the feeder layer for in vitro growth (unpublished data). A similar (but more rapid) progression toward autonomous in vitro growth and high oncogenic potential is observed for bone marrow cells transformed in vitro with A-MuLV (8, 9) .
To define the stages in malignant progression when B lineage cells gain expression of 6C3 antigens, a panel of both non-virus-infected and A-MuLV-infected pre-B and B-cell populations was screened for expression of the 6C3 antigen by immunofluorescence ( Our studies with the bone marrow cultures raise the possibility that the 6C3 proteins represent the product of a cellular oncogene activated by A-MuLV infection. Recently, it has been demonstrated that some A-MuLV-induced tumors that have lost A-MuLV expression have markedly increased transcription of RNA from the cellular homologues of two viral oncogenes, c-myc and c-myb (11, 12) . This situation may be similar to that of the avian leukosis viruses, in which it has been shown that the transforming retrovirus integrates near to and activates the expression of a cellular oncogene (c-myc) but that the virus itself need not maintain continued expression in transformed cells (27) . Further investigation is needed to establish the relationship between the 6C3 proteins and the products of c-myc and other cellular oncogenes.
Although the precise function of the 6C3 proteins in lymphoma cells awaits more detailed characterization, the appearance of these proteins in autonomously growing cells in the absence of added A-MuLV suggests that they may have more general significance in relation to the control of neoplastic B-cell proliferation. Since feeder layer dependence in vitro seems to be related to the production of soluble factors produced by the adherent cell layer (8) , it is conceivable that the 6C3 proteins on independently growing B lineage cells may represent novel B-cell growth factors or receptors for growth factors or other molecules. In this regard it is interesting to note that A-MuLV-transformed fibroblasts produce a tumor growth factor that competes with epidermal growth factor for binding (28) . In any event, further characterization of the structure and function of the 6C3 proteins should provide new insights into the process of B-lymphocyte transformation.
